{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:17:03Z","timestamp":1784776623591,"version":"3.55.0"},"reference-count":21,"publisher":"Medknow","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["smedj"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.11622\/smedj.2016150","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T02:27:53Z","timestamp":1473388073000},"page":"55-71","source":"Crossref","is-referenced-by-count":10,"title":["The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma"],"prefix":"10.4103","volume":"58","author":[{"given":"S","family":"de Mel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SK","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ML","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AC","family":"Tso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LK","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YT","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WJ","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","published-online":{"date-parts":[[2017,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0058-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229658"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12881"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/437852"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(89)90065-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"ref11","article-title":"25 Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 (Oral and Poster Abstracts). American Society of Hematology.","volume-title":"57th Annual Meeting & Exposition","author":"Durie","year":"2015","unstructured":"77. Durie B, Hoering A, Rajkumar SV, et al. 25 Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 (Oral and Poster Abstracts). American Society of Hematology. 57th Annual Meeting & Exposition. Orlando, FL: December 5, 2015."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-374249"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.04.001"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13243"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"ref18","article-title":"727 Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Signifi cantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and\/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537) (Oral and Poster Abstracts). American Society of Hematology.","volume-title":"57th Annual Meeting & Exposition","author":"Moreau","year":"2015","unstructured":"89. Moreau P, Masszi T, Grzasko N, et al. 727 Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Signifi cantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and\/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537) (Oral and Poster Abstracts). American Society of Hematology. 57th Annual Meeting & Exposition. Orlando, FL: December 7, 2015."},{"key":"ref19","article-title":"505 Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM): Keynote-023 (Oral and Poster Abstracts). American Society of Hematology.","volume-title":"57th Annual Meeting & Exposition","author":"San Miguel","year":"2015","unstructured":"90. San Miguel J, Mateos MV, Shah JJ, et al. 505 Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM): Keynote-023 (Oral and Poster Abstracts). American Society of Hematology. 57th Annual Meeting & Exposition. Orlando, FL: December 7, 2015."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00272.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1211\/0022357022241"}],"container-title":["Singapore Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.smj.org.sg\/article\/singapore-myeloma-study-group-consensus-guidelines-management-patients-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:50:49Z","timestamp":1660042249000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.smj.org.sg\/article\/singapore-myeloma-study-group-consensus-guidelines-management-patients-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]},"published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.11622\/smedj.2016150","relation":{},"ISSN":["0037-5675"],"issn-type":[{"value":"0037-5675","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}